CDH3 in Disease: A Potential Drug Target and Biomarker (G1001)
CDH3 in Disease: A Potential Drug Target and Biomarker
The cadherin-3 (CDH3) protein, also known as P-cadherin, is an integral membrane protein that plays a crucial role in cell adhesion and differentiation. CDH3 is primarily expressed in epithelial tissues and is involved in various physiological and pathological processes. Its dysregulation has been implicated in a wide range of diseases, making it an attractive target for therapeutic intervention and a potential biomarker for disease detection and prognosis.
CDH3 in Cancer
Cancer is a complex disease characterized by uncontrolled cell growth and invasion. CDH3 has been found to be overexpressed in numerous cancer types, including breast, ovarian, gastric, and lung cancers. Its upregulation is associated with increased tumor aggressiveness and poor patient prognosis. In breast cancer, higher levels of CDH3 have been observed in invasive ductal carcinoma compared to normal breast tissue, suggesting its involvement in tumor progression and metastasis. Targeting CDH3 with specific inhibitors or monoclonal antibodies has shown promising results in preclinical models, inhibiting tumor growth and metastasis.
CDH3 as a Therapeutic Target
The aberrant expression of CDH3 in cancer cells makes it an intriguing target for therapeutic intervention. Various approaches have been explored to specifically target CDH3 and inhibit its function. One example is the use of small molecule inhibitors that disrupt the interaction between CDH3 and its downstream signaling partners, such as 尾-catenin. These inhibitors prevent CDH3-mediated signaling pathways that promote cell proliferation, invasion, and metastasis. Additionally, monoclonal antibodies targeting CDH3 have shown promising results in preclinical studies by blocking its function or inducing antibody-dependent cellular cytotoxicity (ADCC) against cancer cells.
Moreover, CDH3-targeted therapies can enhance the efficacy of existing treatment modalities. For instance, combining CDH3 inhibitors with standard chemotherapy drugs has shown synergistic effects in reducing tumor growth and metastasis in animal models. This combinatorial approach has the potential to improve patient outcomes and overcome drug resistance commonly observed in cancer treatment.
CDH3 as a Biomarker
In addition to its potential as a therapeutic target, CDH3 holds promise as a biomarker for disease diagnosis and prognosis. Biomarkers are measurable indicators present in the body that can provide insights into disease development, progression, and response to treatment. The detection of CDH3 expression levels in patient samples, such as blood or tissue biopsies, can serve as a diagnostic tool for various diseases.
In breast cancer, for example, CDH3 expression has been correlated with tumor size, lymph node metastasis, and histological grade. High CDH3 expression levels indicate a more aggressive tumor phenotype, suggesting poor prognosis. Thus, quantifying CDH3 expression could aid in determining the optimal treatment strategy and predicting patient outcome. Additionally, monitoring changes in CDH3 expression during treatment can provide valuable information about treatment response and the development of drug resistance.
The potential of CDH3 as a drug target and biomarker opens up exciting avenues for future research and therapeutic development. Further studies are needed to elucidate the underlying mechanisms by which CDH3 contributes to disease progression and metastasis. This knowledge can help refine therapeutic strategies and identify novel targets within the CDH3 signaling network.
Additionally, the development of diagnostic assays to detect CDH3 expression levels in patient samples is crucial for its clinical application as a biomarker. Robust and reliable methods, such as immunohistochemistry or molecular-based techniques, need to be established to accurately quantify CDH3 expression in a clinical setting.
Furthermore, the exploration of combination therapies that include CDH3 inhibitors alongside existing treatment modalities could improve patient outcomes and increase treatment efficacy.
CDH3, or P-cadherin, is an integral membrane protein involved in cell adhesion and differentiation. Its dysregulation has been implicated in various diseases, making it an attractive target for therapeutic intervention. In cancer, CDH3 is overexpressed and associated with poor prognosis. Targeting CDH3 with specific inhibitors or monoclonal antibodies has shown promising results in preclinical models. Moreover, CDH3 holds potential as a biomarker for disease diagnosis, prognosis, and treatment response. Further research is needed to fully understand the role of CDH3 in disease progression and to optimize its clinical applications as a therapeutic target and biomarker.
Protein Name: Cadherin 3
Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types
More Common Targets
A2M | A2MP1 | A4GALT | ABAT | ABCA1 | ABCB1 | ABCB6 | ABCC5 | ABCC9 | ABCF2 | ABCG2 | ABHD11-AS1 | ABHD3 | ABI1 | ABI2 | ACAA1 | ACACA | ACAN | ACE | ACE2 | ACE3P | ACOT8 | ACP5 | ACSF3 | ACTA2-AS1 | ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | AOAH | AP1B1 | AP1G1 | AP1M2 | AP1S1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3S1 | AP4B1-AS1 | APBB1IP | APCDD1L | APELA | APLNR | APOBEC3A_B | APOBEC3B-AS1 | APOBEC3H | APOC4-APOC2 | APOOP2 | APPAT | APTR | AR | ARAP1-AS2 | ARFRP1 | ARHGAP19-SLIT1 | ARHGAP22-IT1 | ARHGAP26-AS1 | ARHGAP26-IT1 | ARHGAP31-AS1 | ARHGEF26-AS1 | ARHGEF33 | ARHGEF38 | ARHGEF38-IT1 | ARHGEF7-AS1 | ARID2 | ARID3A | ARL14EP | ARL15 | ARL17B | ARL2-SNX15 | ARL4A | ARL4C | ARLNC1 | ARMCX4 | ARMCX5-GPRASP2 | ARMCX6 | ARPC1B | ARPC2 | ARPC3 | ARPC4 | ARPC4-TTLL3 | ARPC5 | ARPIN-AP3S2 | ARRDC3-AS1 | ARX | ASAP1-IT2 | ASNSD1 | ASPN | ASTN2-AS1 | ASXL1 | ATAD2B | ATE1-AS1 | ATF4P4 | ATM | ATN1 | ATP11A-AS1 | ATP13A5-AS1 | ATP2A1-AS1 | ATP5PBP5 | ATP5PO | ATP6AP1 | ATP6AP2 | ATP6V0A1 | ATP6V0B | ATP6V0CP1 | ATP6V0E1P1 | ATP6V1FNB | ATP6V1G2 | ATP6V1G2-DDX39B | ATP7A | ATP7B | ATP8B1-AS1 | ATP9A | ATR | ATRX | B3GALT9 | B3GNT6 | BAALC-AS1 | BABAM2-AS1 | BACE1-AS | BANCR | BAX | BBS12 | BCAP31 | BCAR3-AS1 | BCAS2P2 | BCAS3 | BCL11A | BCL2 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L2-PABPN1 | BCO1 | BCRP7 | BECN1 | BEST2 | BHLHA15 | BHLHE40-AS1 | BICRA | BIVM | BIVM-ERCC5 | BLACAT1 | BLOC1S1-RDH5 | BLOC1S5-TXNDC5 | BMPER | BMPR1B-DT | BMS1P17 | BMS1P21 | BMS1P7 | BNC2 | BOK-AS1 | BOLA3-DT | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BPIFB5P | BRAF | BRCA1 | BRINP1 | BRWD1 | BSN-DT | BSPH1 | BSPRY | BTBD1 | BTBD16 | BTG4 | BTN2A3P | BTNL10P | BYSL | C10orf71 | C10orf71-AS1 | C10orf90 | C10orf95-AS1 | C11orf24 | C11orf71 | C11orf91 | C13orf46 | C16orf82 | C16orf95 | C17orf107 | C17orf99 | C18orf54 | C1orf68 | C1QBP | C1QL2 | C1QTNF1-AS1 | C1QTNF3-AMACR | C20orf181 | C21orf58 | C21orf62-AS1 | C21orf91 | C2CD4D | C2CD4D-AS1 | C4B_2 | C4orf46P3 | C5orf52